블로그
- Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in ... Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis Abstract The introduction of CDK4/6 inhibitors
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or ... A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer Abstract Purpose: Inhibition of the cyclin D–cyclin-dependent kinase (CDK)4/6–INK4–retinoblastoma